Study to compare avelumab in combination with standard of care chemoradiotherapy (SoC CRT) versus SoC CRT for definitive treatment in patients with locally advanced squamous cell carcinoma of the head and neck (JAVELIN HEAD AND NECK 100)

A randomized double-blind phase 3 study of avelumab in combination with standard of care chemoradiotherapy (cisplatin plus definitive radiation therapy) versus standard of care chemoradiotherapy in the front-line treatment of patients with locally advanced squamous cell carcinoma of the head and neck

Category & Conditions:

Cancer

Medicine:

Bavencio (avelumab)

ClinicalTrials.gov Identifier (NCT):

NCT02952586

Protocol ID:

B9991016

Print Download

Open Plain Language Summary Result:Click here

Maintaining Emotional Well-Being During COVID-19

MRNA VS. CONVENTIONAL VACCINES

Working Together to Empower Women

Reducing Health Disparities in Latino Communities

Pfizer Women’s Resource Group

Universal vs. Single Payer Healthcare

Study to compare avelumab in combination with standard of care chemoradiotherapy (SoC CRT) versus SoC CRT for definitive treatment in patients with locally advanced squamous cell carcinoma of the head and neck (JAVELIN HEAD AND NECK 100)